Mepolizumab decreases urinary excretion of LTE4 in severe asthma

V. Yasinska (Stockholm, Sweden), J. Kolmert (Stockholm, Sweden), J. Zurita (Stockholm, Sweden), A. Quaranta (Stockholm, Sweden), A. Bossios (Stockholm, Sweden), N. Lazarinis (Stockholm, Sweden), B. Dahlén (Stockholm, Sweden), C. E. Wheelock (Stockholm, Sweden), S. Dahlén (Stockholm, Sweden), .. (on Behalf Of The Biocross Study Group) (Stockholm, Sweden)

Source: Virtual Congress 2020 – New insight into the pathogenesis of chronic lung diseases: asthma, COPD and others
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
V. Yasinska (Stockholm, Sweden), J. Kolmert (Stockholm, Sweden), J. Zurita (Stockholm, Sweden), A. Quaranta (Stockholm, Sweden), A. Bossios (Stockholm, Sweden), N. Lazarinis (Stockholm, Sweden), B. Dahlén (Stockholm, Sweden), C. E. Wheelock (Stockholm, Sweden), S. Dahlén (Stockholm, Sweden), .. (on Behalf Of The Biocross Study Group) (Stockholm, Sweden). Mepolizumab decreases urinary excretion of LTE4 in severe asthma. 2046

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: